Evidence map›Paper›PMID 28420081›Full record

ReviewInternational journal of molecular sciences2017

Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors.

Stefania Moz, Ada Aita, Daniela Basso, Roberta Ramonda, Mario Plebani, Leonardo Punzi

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. ABMC musculoskeletal disorders · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Role of Semaphorins in Immunopathologies and Rheumatic Diseases.International journal of molecular sciences · 2019
    Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Stefania MozLaboratory Medicine, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. stefania.moz@studenti.unipd.it.
Ada AitaLaboratory Medicine, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. ada.aita@tiscali.it.
Daniela BassoLaboratory Medicine, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. daniela.basso@unipd.it.
Roberta RamondaRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. roberta.ramonda@unipd.it.
Mario PlebaniLaboratory Medicine, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. mario.plebani@unipd.it.
Leonardo PunziRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. leonardo.punzi@unipd.it.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term spondyloarthritis (SpA) is used to describe a group of multifactorial chronic inflammatory diseases characterized by a predisposing genetic background and clinical manifestations typically involving the sacroiliac joint. The absence of pathognomonic clinical and/or laboratory findings generally results in a delay in diagnosis and, consequently, in treatment. In addition, 20-40% of SpA patients are non-responders to tumor necrosis factor (TNF) inhibitor therapies. Given these considerations, it is important to identify biomarkers that can facilitate the diagnosis and assessment of disease activity. As inflammation plays a key role in the pathogenesis of SpA, inflammatory mediators have been investigated as potential biomarkers for diagnosing the disease and predicting response to therapy. Some investigators have focused their attention on the role of matrix metalloproteinases (MMPs), which are known to be markers of synovial inflammation that is generated in the joint in reaction to inflammatory stimuli. Several studies have been carried out to verify if serum MMPs levels could be useful to diagnose SpA, to assess disease severity, and to predict response to TNF inhibitor therapy. The current review focuses on MMPs' role in SpA pathogenesis, diagnosis and therapeutic implications.

Indexed as

AnimalsBiomarkersCartilageExtracellular MatrixGenetic Predisposition to DiseaseHumansImmunityInflammationMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMolecular Targeted TherapyPhenotypeSpondylarthropathiesTumor Necrosis Factor-alphaBiomarkersMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesTumor Necrosis Factor-alphabiomarkersinflammationmatrix metalloproteinases (MMPs)spondyloarthritis (SpA)TNF inhibitorstumor necrosis factor (TNF)

Identifiers

PMID28420081
PMCPMC5412414
OpenAlexW2605789765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.